United States In Vitro Diagnostics Market Analysis
The United States In-Vitro Diagnostics (IVD) market is poised for substantial growth, with an expected valuation of US$ 56.52 billion by 2030, as forecasted by Renub Research. This market growth is driven by technological innovations, improved accuracy, and quicker diagnostic results. In-vitro diagnostics (IVD) involves tests conducted on biological samples like blood or tissue outside the body, playing a critical role in disease diagnosis, monitoring, and treatment. As personalized medicine and early disease detection become more prevalent, the demand for advanced IVD solutions is surging across healthcare facilities, leading to better patient outcomes and more efficient healthcare systems.
Request a free sample copy of the report: https://www.renub.com/automotive-actuators-market-p.php
Market Growth: Fueling Innovation and Expanding Healthcare Access
The U.S. IVD market is anticipated to grow at a CAGR of 4.62% from 2024 to 2030. This growth reflects key trends, such as the increasing automation of diagnostic systems that boost efficiency, accuracy, and throughput. As a result, the U.S. is solidifying its position as a global leader in in-vitro diagnostic technologies. The rise in chronic diseases and infectious illnesses further supports this growth. According to the American Cancer Society, in 2023, nearly 1.96 million new cancer diagnoses were expected, alongside approximately 609,820 cancer-related deaths. This alarming statistic underscores the growing need for advanced diagnostic solutions.
Additionally, the aging population in the United States is a key driver of the market. With over 54 million Americans aged 65 and above in 2023, representing 16.5% of the total population, this demographic is expected to increase significantly over the coming decades. By 2050, the number of senior citizens is projected to exceed 85.7 million. Aging individuals often require regular health monitoring for age-related conditions like cardiovascular disease, diabetes, and cancer, which boosts demand for frequent and accurate diagnostic testing.
In 2023, the U.S. In-Vitro Diagnostics market was valued at US$ 41.19 billion, and this upward trajectory is expected to continue as advanced diagnostic technologies improve early detection and treatment options.
Technological Innovations Driving IVD Market Expansion
Technological advancements are transforming the IVD landscape. Innovations like next-generation sequencing, digital PCR, and advanced imaging techniques promise to enhance testing accuracy, sensitivity, and specificity. These breakthroughs are not only enabling earlier disease detection but also offering personalized treatment plans, thus improving patient outcomes. The integration of cutting-edge technologies into diagnostic workflows is expected to make diagnostic testing more efficient, reducing healthcare costs and improving the overall quality of care.
These innovations are leading to significant improvements in how diseases are diagnosed, especially genetic disorders, infectious diseases, and cancers, while streamlining laboratory processes and ensuring faster results.
PCR Technology: A Key Growth Driver
Among the various test types used in in-vitro diagnostics, Polymerase Chain Reaction (PCR) technology is gaining momentum. PCR is known for its versatility, sensitivity, and wide application across a range of medical conditions. PCR-based tests are essential in diagnosing infectious diseases, genetic disorders, and cancers, offering accurate and rapid results. The advancements in real-time PCR and digital PCR technologies have further expanded the capabilities of PCR in medical diagnostics. These improvements make PCR-based testing a cornerstone of modern diagnostic practices, contributing to its expected growth in the U.S. IVD market.
Instruments Set to Lead the U.S. IVD Market
In terms of product segments, instruments are expected to be a dominant category in the U.S. IVD market. Automated diagnostic instruments are integral to performing tests with higher throughput and greater accuracy. The demand for high-performance diagnostic instruments is growing as medical laboratories and healthcare facilities seek reliable and efficient solutions for diagnostic testing.
These instruments, which support a range of applications, from molecular diagnostics to immunochemistry, are revolutionizing how tests are conducted, allowing for faster results, better patient care, and streamlined operations in clinical environments. Their growing importance underscores their central role in the future of in-vitro diagnostics in the U.S.
Hematology: One of the Fastest-Growing Segments in IVD
By application, the hematology segment is expected to see some of the most significant growth within the U.S. IVD market. Blood disorders such as anemia, leukemia, and hemophilia are becoming more prevalent, driving the need for accurate and timely diagnostics. Hematology tests are vital for diagnosing, monitoring, and treating these conditions.
In addition to the increasing incidence of blood-related diseases, advancements in hematology analyzers, which include better automation and the integration of advanced parameters, are fueling the adoption of hematology tests. As these technologies evolve, hematology is poised to become a key area of growth within the IVD sector, offering enhanced diagnostic capabilities for healthcare providers.
Key Players in the U.S. In-Vitro Diagnostics Market
The U.S. IVD market is dominated by several major players, including Roche Diagnostics, Danaher Corporation, Thermo Fisher Scientific, Bio-Rad Laboratories, BioMerieux, Abbott Laboratories, and Sysmex Corporation. These companies are at the forefront of innovation in diagnostic technologies, continually introducing new products and solutions that cater to evolving healthcare needs.
For example, in March 2023, Atila Biosystems and Stilla Technologies teamed up to offer co-labeled digital PCR equipment, enhancing the precision of PCR-based tests. Additionally, QIAGEN launched the EZ2 Connect MDx platform in January 2023, an innovation designed to streamline sample processing and improve automation for PCR and qPCR applications.
Related Report :
Salivary Gland Infection Market
Europe Next Generation Sequencing Market
United States Next Generation Sequencing Market
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com